Nevro Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1,099

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $250M

Nevro General Information

Description

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Contact Information

Website
www.nevro.com
Formerly Known As
NBI Development
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 1800 Bridge Parkway
  • Redwood City, CA 94065
  • United States
+1 (650)
Primary Industry
Therapeutic Devices
Parent Company
Globus Medical
Corporate Office
  • 1800 Bridge Parkway
  • Redwood City, CA 94065
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nevro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 03-Apr-2025 $250M Completed Profitable
10. Debt - Acquisition 30-Nov-2023 Completed Profitable
9. Secondary Transaction - Open Market 03-Apr-2017 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Open Market 09-Jun-2016 Completed Generating Revenue/Not Profitable
7. Secondary Transaction - Open Market 23-Mar-2016 Completed Generating Revenue/Not Profitable
6. 2PO 03-Jun-2015 Completed Generating Revenue/Not Profitable
5. Debt - General 15-Dec-2014 Completed Generating Revenue
4. IPO 06-Nov-2014 Completed Generating Revenue
3. Later Stage VC (Series C) 08-Feb-2013 $48M $154M Completed Generating Revenue
2. Early Stage VC (Series B) 19-Jul-2011 $58.6M $106M Completed Startup
To view Nevro’s complete valuation and funding history, request access »

Nevro Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A 130,508,081 $0.001000 8% $0.36 1x $0.36 30.35%
To view Nevro’s complete cap table history, request access »

Nevro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which include
Therapeutic Devices
Redwood City, CA
1,099 As of 2024

Alameda, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nevro Competitors (20)

One of Nevro’s 20 competitors is Penumbra, a Formerly VC-backed company based in Alameda, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Penumbra Formerly VC-backed Alameda, CA
Mainstay Medical Venture Capital-Backed San Diego, CA
ZetrOZ Venture Capital-Backed Trumbull, CT
Saluda Medical Private Equity-Backed Artarmon, Australia
BioWave Venture Capital-Backed Norwalk, CT
You’re viewing 5 of 20 competitors. Get the full list »

Nevro Patents

  • 756

    Total Documents Applications and Grants

  • Total Patents Families

  • 563

    Granted

  • 69

    Pending

  • Expiring in next 12 mo

Nevro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023364560-A1 Systems and methods for delivering neurostimulation, including maintenance doses of neurostimulation for maintaining a patient in a state of remission Pending 21-Oct-2022
US-20240017068-A1 Systems and methods for delivering neurostimulation, including reduced doses of neurostimulation Pending 15-Jul-2022
AU-2023305684-A1 Systems and methods for delivering neurostimulation, including reduced doses of neurostimulation Pending 15-Jul-2022
US-20240001121-A1 Neurostimulation for treating sensory deficits, and associated systems and methods Active 01-Jul-2022
AU-2023299284-A1 Neurostimulation for treating sensory deficits, and associated systems and methods Pending 01-Jul-2022 A61N1/36062
To view Nevro’s complete patent history, request access »

Nevro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nevro Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aberdare Ventures Venture Capital Minority
Accuitive Medical Ventures Venture Capital Minority
Bay City Capital Venture Capital Minority
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority
MPM BioImpact Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Nevro Acquisitions (1)

Nevro’s most recent deal was a Merger/Acquisition with Vyrsa Technologies for . The deal was made on 30-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vyrsa Technologies 30-Nov-2023 Merger/Acquisition Surgical Devices
To view Nevro’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Nevro ESG

Risk Overview

Risk Rating

Updated September, 16, 2023

21.95 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Healthcare

Industry

of 587

Rank

Percentile

Medical Devices

Subindustry

of 198

Rank

Percentile

To view Nevro’s complete esg history, request access »

Nevro Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Vyrsa Technologies King of Prussia, PA 2021

Nevro FAQs

  • When was Nevro founded?

    Nevro was founded in 2006.

  • Where is Nevro headquartered?

    Nevro is headquartered in Redwood City, CA.

  • What is the size of Nevro?

    Nevro has 1,099 total employees.

  • What industry is Nevro in?

    Nevro’s primary industry is Therapeutic Devices.

  • Is Nevro a private or public company?

    Nevro is a Private company.

  • What is the current valuation of Nevro?

    The current valuation of Nevro is .

  • What is Nevro’s current revenue?

    The current revenue for Nevro is .

  • How much funding has Nevro raised over time?

    Nevro has raised $390M.

  • Who are Nevro’s investors?

    Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson Innovation - JJDC, and MPM BioImpact are 5 of 11 investors who have invested in Nevro.

  • Who are Nevro’s competitors?

    Penumbra, Mainstay Medical, ZetrOZ, Saluda Medical, and BioWave are some of the 20 competitors of Nevro.

  • When was Nevro acquired?

    Nevro was acquired on 03-Apr-2025.

  • Who acquired Nevro?

    Nevro was acquired by Globus Medical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »